◀ Back to MAPK1
MAP2K2 — MAPK1
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(directlyIncreases, MAP2K2 Activity, MAPK1 Activity)
Evidence: Once activated, Raf-1 phosphorylates serines in the catalytic sites of MKK/MEK [345,367]. MKK1/MEK1 and MKK2/MEK2 activate members of the MAP kinase family (ERK-1/ERK-2),
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(directlyIncreases, MAP2K2 Activity, MAPK1 Activity)
Forcet et al., Nature 2002
Evidence: in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(directlyIncreases, MAPK1 Activity)
Kapoor et al., J Lipid Res 2003*
Evidence: Sp1, SRE-1 binding protein, and CBP are part of the transcriptional complex resulting in induction of LDL receptor expression in response to activation of the Raf/MEK/p42/44MAPK cascade. MEK=MAP2K1,2 p42=MAPK1 44MAP=MAPK3
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(directlyIncreases, MAPK1 Activity)
Forcet et al., Nature 2002
Evidence: in embryonic kidney cells expressing full-length DCC, NTN1 causes increased transient phosphorylation and activity of ERK1 and ERK2 but not of JNK1, JNK2 or MAPK14 this phosphorylation was mediated by MAP2K1 (aka MEK1) and/or MAP2K2 (aka MEK2)
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(directlyIncreases, MAPK1 Activity)
Evidence: Despite remarkable progress in dissecting the signaling pathways that are crucial for the metabolic effects of insulin, the molecular basis for the specificity of its cellular actions is not fully understood. One clue might lie in the spatial and temporal aspects of signaling. Recent evidence suggests that signaling molecules and pathways are localized to discrete compartments in cells by specific protein interactions. Also, the rapid termination of tyrosine or lipid phosphorylation by phosphata...
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
MAP2K2
(increases, MAPK1 Activity)
Liu et al., Biochem Biophys Res Commun 2001*
Evidence: PD98059--a specific inhibitor of MAP or Erk kinase 1 (MEK 1), the upstream kinase that phosphorylates Erk1/2--abolishes angiogenin-induced Erk phosphorylation and cell proliferation without affecting nuclear translocation of angiogenin.
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
RAF1
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK2 (MAPK1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
MEK2 (MAP2K2)
→
ERK2 (MAPK1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
dynamin gtpase (DNM1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
dynamin gtpase (DNM1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, activates)
-
BioCarta keratinocyte differentiation:
MEK2 (MAP2K2)
→
ERK2 (MAPK1)
(modification, activates)
-
BioCarta mapkinase signaling pathway:
MEK1/MEK2 (MAP2K2/MAP2K1)
→
ERK1/ERK2 (MAPK3/MAPK1)
(modification, activates)
-
KEGG Vascular smooth muscle contraction:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG VEGF signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Gap junction:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Toll-like receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Natural killer cell mediated cytotoxicity:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG T cell receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG B cell receptor signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Fc epsilon RI signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Long-term potentiation:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Neurotrophin signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Long-term depression:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Regulation of actin cytoskeleton:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Insulin signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG GnRH signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Melanogenesis:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG MAPK signaling pathway:
MAP2K2
→
MAPK1/MAPK3
(protein-protein, phosphorylation)
-
KEGG Prion diseases:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Influenza A:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Pathways in cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Renal cell carcinoma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Endometrial cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Glioma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Glioma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3/PIK3CA/PIK3CB/PIK3CD/PIK3CG
(protein-protein, activation)
-
KEGG Prostate cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Thyroid cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Thyroid cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Melanoma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Bladder cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Chronic myeloid leukemia:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Acute myeloid leukemia:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG Non-small cell lung cancer:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
KEGG ErbB signaling pathway:
MAP2K1/MAP2K2
→
MAPK1/MAPK3
(protein-protein, activation)
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2-active (MAPK3/MAPK1)
→
MEK1/MEK2 complex (MAP2K1-MAP2K2)
(modification, activates)
Catalanotti et al., Nature structural & molecular biology 2009, Brunet et al., FEBS Lett 1994*
Evidence: assay
-
NCI Pathway Database PDGFR-beta signaling pathway:
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-MAP2K1_MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
KSR/14-3-3 (dimer)/MEK1-2 complex (KSR1-MAP2K1_MAP2K2)
(modification, activates)
McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database mTOR signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Roux et al., Proc Natl Acad Sci U S A 2004, Ma et al., Cell 2005
-
NCI Pathway Database mTOR signaling pathway:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Roux et al., Proc Natl Acad Sci U S A 2004, Ma et al., Cell 2005
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Bernatchez et al., Br J Pharmacol 2001
Evidence: genetic interaction
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Bernatchez et al., Br J Pharmacol 2001
Evidence: genetic interaction
-
NCI Pathway Database CXCR3-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Bonacchi et al., J Biol Chem 2001, Smit et al., Blood 2003
Evidence: assay
-
NCI Pathway Database CXCR3-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Bonacchi et al., J Biol Chem 2001, Smit et al., Blood 2003
Evidence: assay
-
NCI Pathway Database Netrin-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Forcet et al., Nature 2002, Hérincs et al., J Cell Sci 2005
Evidence: genetic interaction, mutant phenotype
-
NCI Pathway Database Netrin-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Forcet et al., Nature 2002, Hérincs et al., J Cell Sci 2005
Evidence: genetic interaction, mutant phenotype
-
NCI Pathway Database IL2-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2 (MAP2K1/MAP2K2)
(modification, collaborate)
Perkins et al., J Exp Med 1993*
Evidence: mutant phenotype, other species
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1/MEK2 complex (MAP2K1-MAP2K2)
(modification, collaborate)
Catalanotti et al., Nature structural & molecular biology 2009
Evidence: assay
-
NCI Pathway Database ErbB1 downstream signaling:
MEK1/MEK2 complex (MAP2K1-MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Catalanotti et al., Nature structural & molecular biology 2009
Evidence: assay
-
NCI Pathway Database ErbB2/ErbB3 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Monje et al., J Biol Chem 2008, Vijapurkar et al., J Biol Chem 1998
Evidence: assay
-
NCI Pathway Database ErbB2/ErbB3 signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Monje et al., J Biol Chem 2008, Vijapurkar et al., J Biol Chem 1998
Evidence: assay
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2 (MAP2K1/MAP2K2)
(modification, collaborate)
Crews et al., Proc Natl Acad Sci U S A 1992*
Evidence: assay, other species
-
NCI Pathway Database GMCSF-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Guthridge et al., Blood 2004, Lanfrancone et al., Oncogene 1995, Sato et al., EMBO J 1993, Itoh et al., Mol Cell Biol 1998*, Jenkins et al., Blood 1998*
Evidence: genetic interaction
-
NCI Pathway Database GMCSF-mediated signaling events:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Guthridge et al., Blood 2004, Lanfrancone et al., Oncogene 1995, Sato et al., EMBO J 1993, Itoh et al., Mol Cell Biol 1998*, Jenkins et al., Blood 1998*
Evidence: genetic interaction
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
Catalanotti et al., Nature structural & molecular biology 2009, McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: assay
-
NCI Pathway Database Endothelins:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Yogi et al., Arterioscler Thromb Vasc Biol 2007
-
NCI Pathway Database Endothelins:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Yogi et al., Arterioscler Thromb Vasc Biol 2007
-
NCI Pathway Database Nongenotropic Androgen signaling:
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Unni et al., Cancer Res 2004, Cheng et al., Endocrinology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Nongenotropic Androgen signaling:
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Unni et al., Cancer Res 2004, Cheng et al., Endocrinology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
Erk1-2 (MAPK3/MAPK1)
→
MEK1-2-active (MAP2K1/MAP2K2)
(modification, collaborate)
Karihaloo et al., J Biol Chem 2001*, Paumelle et al., Oncogene 2002
Evidence: assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
MEK1-2-active (MAP2K1/MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Karihaloo et al., J Biol Chem 2001*, Paumelle et al., Oncogene 2002
Evidence: assay
-
Reactome Reaction:
MAPK1
→
MAP2K2
(reaction)
Yang et al., J Biol Chem 2003*, Xiong et al., J Biol Chem 2003*, Preger et al., Proc Natl Acad Sci U S A 2004*, Torii et al., Dev Cell 2004*, Ziv et al., J Biol Chem 2006*, Zheng et al., J Biol Chem 1993*
-
Reactome Reaction:
MAPK1
→
MAP2K2
(direct_complex)
Zheng et al., J Biol Chem 1993*
-
WikiPathways ESC Pluripotency Pathways:
MAP2K1/MAP2K3/SEPP1/MAP2K5/MAP2K6/MAP2K2
→
MAPK7/MAPK1/MAPK6/MAPK4/MAPK12
(activation)
-
WikiPathways Focal Adhesion:
SEPP1/MAP2K5/MAP2K6/MAP2K2/MAP2K3/MAP2K1
→
MAPK4/MAPK7/MAPK12/MAPK1/MAPK6
(activation)
-
WikiPathways MAPK Cascade:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
-
WikiPathways MicroRNAs in cardiomyocyte hypertrophy:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
-
WikiPathways Regulation of Actin Cytoskeleton:
MAP2K1/MAP2K2
→
MAPK1/MAPK3/MAPK4/MAPK6
(activation)
-
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling:
MAP2K2
→
MAPK1
(mim-necessary-stimulation)
Hetman et al., J Biol Chem 2002*
-
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling:
MAP2K2
→
MAPK1
(mim-necessary-stimulation)
Hetman et al., J Biol Chem 2002*
-
WikiPathways Signaling Pathways in Glioblastoma:
MAP2K1/MAP2K2/MAP2K3/MAP2K4/MAP2K5/MAP2K6/MAP2K7
→
MAPK1/MAPK3
(mim-stimulation)
-
WikiPathways Signaling of Hepatocyte Growth Factor Receptor:
MAP2K2/MAP2K1
→
MAPK1/MAPK3
(activation)
-
WikiPathways Structural Pathway of Interleukin 1 (IL-1):
MAP2K2
→
MAPK3/MAPK1
(activation)
-
WikiPathways 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression:
Complex of MAP2K2-MAP2K1
→
Complex of MAPK1-MAPK3
(activation)
-
WikiPathways Cardiac Hypertrophic Response:
MAP2K2/MAP2K1
→
MAPK3/MAPK1
(activation)
-
WikiPathways Common Pathways Underlying Drug Addiction:
MAP2K1/MAP2K2
→
MAPK3/MAPK1
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind Interaction:
MAP2K2
—
MAPK1
Bardwell et al., J Biol Chem 2001*
-
IRef Bind_translation Interaction:
MAP2K2
—
MAPK1
(affinity chromatography technology)
Bardwell et al., J Biol Chem 2001*
-
IRef Bind_translation Interaction:
MAP2K2
—
MAPK1
(competition binding)
Bardwell et al., J Biol Chem 2001*
-
IRef Biogrid Interaction:
MAP2K2
—
MAPK1
(direct interaction, protein complementation assay)
Srivastav et al., Biochem J 2011
-
IRef Biogrid Interaction:
MAP2K2
—
MAPK1
(direct interaction, enzymatic study)
Ho et al., J Biol Chem 2003
-
IRef Biogrid Interaction:
MAP2K2
—
MAPK1
(direct interaction, pull down)
Ho et al., J Biol Chem 2003
-
IRef Biogrid Interaction:
MAP2K2
—
MAPK1
(direct interaction, two hybrid)
Robinson et al., J Biol Chem 2002*
-
IRef Hprd Interaction:
Complex of 17 proteins
(in vivo)
Stewart et al., Mol Cell Biol 1999
-
IRef Hprd Interaction:
MAP2K2
—
MAPK1
(two hybrid)
Bardwell et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*
-
IRef Hprd Interaction:
MAP2K2
—
MAPK1
(in vitro)
Bardwell et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*
-
IRef Hprd Interaction:
MAP2K2
—
MAPK1
(in vivo)
Bardwell et al., J Biol Chem 2001*, Robinson et al., J Biol Chem 2002*
-
IRef Ophid Interaction:
MAP2K2
—
MAPK1
(aggregation, confirmational text mining)
Robinson et al., J Biol Chem 2002*
-
IRef Ophid Interaction:
MAP2K2
—
MAPK1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Martel-Pelletier et al., Arthritis Rheum 1999
(Osteoarthritis) :
Within minutes, IL-17 induced the phosphorylation of
mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 ) ... Within minutes, IL-17 induced the phosphorylation of mitogen activated protein kinase kinase-1/2 (
MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
Newton et al., Br J Pharmacol 2000
:
We have therefore used these cells to examine the effect of the selective
mitogen activated protein ( MAP ) kinase inhibitors ; PD098059, a mitogen activated and extracellular regulated kinase kinase ( MEK) 1 inhibitor, UO126, a dual MEK1 &
MEK2 inhibitor , and SB203580, a p38 MAP kinase inhibitor in the IL-1beta dependent release of PGE ( 2 )
Kim et al., IUBMB Life 2000
:
S1P treatment transiently activated
Erk-1/-2 in a dose dependent manner, and its activation was
blocked by pertussis toxin, expression of RasN17, or inhibition of Raf or
MEK-1/-2
Tu et al., J Biomed Sci 2001
(Carcinoma, Hepatocellular) :
On the other hand, PD98059, a specific inhibitor of
mitogen activated protein kinase kinase ,
blocks TPA induced
MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Huang et al., Biochem Biophys Res Commun 2003
:
MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a
mitogen activated protein kinase kinase ( MAP2K ), which in turn
activates a
mitogen activated protein kinase ( MAPK )
Sananbenesi et al., J Neurosci 2003
(MAP Kinase Signaling System) :
Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 ( aSvg-30 ) prevented stress enhanced fear conditioning and
Mek-1/2 dependent
activation of
Erk-1/2 and p90Rsk-1
de Bernardo et al., J Neurochem 2004
:
MEK-1/2 and lipoxygenase (LOX) inhibitors, as well as ascorbic acid,
prevent ERK-1/2 activation and neuronal loss, but the inhibition of nitric oxide sintase (NOS), cyclo-oxygenase (COX), c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein kinase ( p38 MAPK ) does not have protective effects
Aroor et al., Alcohol 2009
:
These results suggest that Ang II-mediated accumulation of phospho-p42/44
MAPK in the hepatocyte nucleus
involves MEK 1/2 dependent activation and this effect is potentiated by ethanol
Malarkannan et al., J Immunol 2012
:
This includes actin polymerization, tubulin multimerization, microtubule organizing center formation, calcium/calmodulin signaling,
Pak/Raf/Mek1/2 mediated
Erk1/2 activation, formation of maestrosome, E-cadherin, and CD44 mediated signaling and glycogen synthase kinase-3/adenomatous polyposis coli mediated ß-catenin activation
Huwiler et al., Br J Pharmacol 1994
:
2. Both nucleotides stimulate phosphorylation and
activation of
mitogen activated protein kinase and a biphasic phosphorylation of the up-stream
mitogen activated protein kinase kinase
Bazan et al., Curr Eye Res 1997
:
Corneal tissue expresses ERK2 or MAPK, and both MEK1 and
MEK2 , the immediate upstream
regulators of
MAPK
Daum et al., FEBS Lett 1998
:
Pervanadate inhibits
mitogen activated protein kinase kinase-1 in a
p38MAPK dependent manner
Tsatsanis et al., Oncogene 1998
(Lymphoma, T-Cell) :
Since the activation of NFAT is MAPK dependent these findings suggested that the activation of
MAPK by Tpl-2 is either independent or only partially
dependent on MEK1 and
MEK2